Emyria

Stay up to date with Emyria's endeavours and celebrate our milestones.

Pipeline

Contact Us

Meet the Team

Announcements

New investors

Corporate Governance

Why Invest in Emyria?

Updates

About Emyria

Home

Montserrat

Emyria Limited

Interim Clinical Results for PTSD Program

We've recently released a progress report of our PTSD Program.

Interim analysis of the first eight patients completing Emyria’s MDMA-assisted therapy (MDMA-AT) PTSD program shows all patients achieved substantial improvement in PTSD symptoms, with a clinically and statistically significant average reduction of 33 points in PCL-5 scores.

All patients reported substantial gains in quality of life.

Emyria continues to evolve its leading care programs by actively collecting and applying Real-World Data, setting the pace and standards for PTSD care globally.

Plans are underway to sustainably expand these programs, in close partnership with private hospitals and third-party payers.

Emyria’s second psychiatrist receives "Authorised Prescriber" (AP) approval from the TGA.

Authorisation reflects Emyria's dedication to expanding mental health care treatment
options under the strict regulatory, ethical, and safety frameworks mandated by the TGA.

Emyria’s second AP is believed to be the first, and currently only, female Authorised
Prescriber for MDMA-assisted therapy in Australia.

An additional AP increases Emyria’s capacity for trials and patient care, and aligns with
current clinical facility expansion efforts

Emyria Opens Empax Centre to Advance Mental Health Care

Our first "Empax Centre" is a bespoke facility dedicated to the delivery and development of new treatments for mental health such as MDMA-assisted therapy (MDMA-AT) for PTSD.

Led by some of Australia's first Authorised Prescribers, Empax Centre features advanced technology for superior patient care and data-driven research.

Empax Centre is aiming at operational profitability by H2 2024 with the potential for further national and global expansion

Empax Centre to initially target critical gaps in care for resistant PTSD, with a strategy to expand therapeutic offerings using the same foundational infrastructure.

View the latest ASX release on this initiative

View the latest ASX release on this initiative